OTR-话题@MedSci

#OTR#

34篇内容 | 908人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1631257, encodeId=6737163125ee6, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=NEJM：Larotrectinib对TRK融合阳性肿瘤治疗效果显著, objectType=article, longId=130286, objectId=a7911302861d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7911302861d, replyNumber=0, likeNumber=26, createdTime=2018-02-24, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7911302861d, moduleTitle=NEJM：Larotrectinib对TRK融合阳性肿瘤治疗效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7911302861d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631256, encodeId=3f0116312567c, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=SCI REP：尿液Endotrophin预测慢性肾脏疾病患者疾病进展！, objectType=article, longId=123269, objectId=8c0c1232696a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c0c1232696a, replyNumber=0, likeNumber=17, createdTime=2017-12-14, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c0c1232696a, moduleTitle=SCI REP：尿液Endotrophin预测慢性肾脏疾病患者疾病进展！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c0c1232696a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631255, encodeId=dbc8163125569, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=CFDA批准上市Votrient®（培唑帕尼），用于晚期肾细胞癌患者治疗, objectType=article, longId=121902, objectId=67b612190234, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67b612190234, replyNumber=0, likeNumber=25, createdTime=2017-12-02, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67b612190234, moduleTitle=CFDA批准上市Votrient®（培唑帕尼），用于晚期肾细胞癌患者治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67b612190234)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631254, encodeId=ab761631254b9, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=CFDA批准上市Giotrif®（阿法替尼），单药治疗EGFR敏感突变的晚期非小细胞肺癌, objectType=article, longId=121901, objectId=1fe812190145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fe812190145, replyNumber=0, likeNumber=22, createdTime=2017-12-02, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fe812190145, moduleTitle=CFDA批准上市Giotrif®（阿法替尼），单药治疗EGFR敏感突变的晚期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fe812190145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631253, encodeId=eda91631253b7, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=ASCO 2017：热点聚焦——新药Larotrectinib（LOXO-101）治疗各种成人及儿童癌症效果卓越, objectType=article, longId=100851, objectId=2b3910085190, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b3910085190, replyNumber=0, likeNumber=33, createdTime=2017-06-07, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b3910085190, moduleTitle=ASCO 2017：热点聚焦——新药Larotrectinib（LOXO-101）治疗各种成人及儿童癌症效果卓越, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b3910085190)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631252, encodeId=8aa6163125218, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=疗效不佳，勃林格殷格翰终止两项Gilotrif 头颈癌临床试验, objectType=article, longId=74794, objectId=21e6e479462, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21e6e479462, replyNumber=0, likeNumber=31, createdTime=2016-08-10, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21e6e479462, moduleTitle=疗效不佳，勃林格殷格翰终止两项Gilotrif 头颈癌临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21e6e479462)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631251, encodeId=38d8163125166, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=J NEUROTRAUM：脑震荡后女孩酗酒风险增加，改变环境可降低风险, objectType=article, longId=57316, objectId=54b25e316f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54b25e316f9, replyNumber=0, likeNumber=37, createdTime=2015-10-17, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54b25e316f9, moduleTitle=J NEUROTRAUM：脑震荡后女孩酗酒风险增加，改变环境可降低风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54b25e316f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631250, encodeId=29e1163125038, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=The Lancet Oncology：勃林格靶向药物Giotrif治疗肺部鳞状细胞癌疗效优于Tarceva, objectType=article, longId=53024, objectId=3eb75302455, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eb75302455, replyNumber=0, likeNumber=33, createdTime=2015-07-10, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eb75302455, moduleTitle=The Lancet Oncology：勃林格靶向药物Giotrif治疗肺部鳞状细胞癌疗效优于Tarceva, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eb75302455)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631249, encodeId=48f5163124949, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=PLoS One：Tiotropium治疗慢性阻塞性肺病效果略优于Indacaterol, objectType=article, longId=48762, objectId=089348e622c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=089348e622c, replyNumber=0, likeNumber=32, createdTime=2015-04-01, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=089348e622c, moduleTitle=PLoS One：Tiotropium治疗慢性阻塞性肺病效果略优于Indacaterol, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=089348e622c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631248, encodeId=90ad163124805, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=Spine J：Cotrel-Dubousset 装置的棒大小不影响 AIS 患者的手术结果, objectType=article, longId=39136, objectId=d11b39136b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d11b39136b6, replyNumber=0, likeNumber=29, createdTime=2014-08-16, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d11b39136b6, moduleTitle=Spine J：Cotrel-Dubousset 装置的棒大小不影响 AIS 患者的手术结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d11b39136b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631247, encodeId=bc61163124ede, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=勃林格殷格翰向欧盟提交tiotropium Respimat®扩大适应症申请, objectType=article, longId=26620, objectId=34aa26620b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34aa26620b7, replyNumber=0, likeNumber=38, createdTime=2013-11-16, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34aa26620b7, moduleTitle=勃林格殷格翰向欧盟提交tiotropium Respimat®扩大适应症申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34aa26620b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631246, encodeId=754d1631246e9, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=勃林格殷格翰抗癌药Giotrif（afatinib）获欧盟批准, objectType=article, longId=25213, objectId=d462252130c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d462252130c, replyNumber=0, likeNumber=35, createdTime=2013-10-10, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d462252130c, moduleTitle=勃林格殷格翰抗癌药Giotrif（afatinib）获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d462252130c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631245, encodeId=df141631245b2, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=FDA：葛兰素史克向欧盟提交Votrient新适应症申请, objectType=article, longId=22808, objectId=15c92280847, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15c92280847, replyNumber=0, likeNumber=29, createdTime=2013-08-10, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15c92280847, moduleTitle=FDA：葛兰素史克向欧盟提交Votrient新适应症申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15c92280847)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631244, encodeId=7c021631244bf, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, objectTitle=FDA批准Gilotrif用于肺癌患者, objectType=article, longId=22437, objectId=bc7d2243ef2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7d2243ef2, replyNumber=0, likeNumber=22, createdTime=2013-08-02, rootId=0, userName=jichang, userId=fb2621702447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7d2243ef2, moduleTitle=FDA批准Gilotrif用于肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7d2243ef2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

OTR

2020-05-29

jichang (审核中...)

前往app查看评论内容

#OTR#

NEJM：Larotrectinib对TRK融合阳性肿瘤治疗效果显著

2018-02-24

jichang (审核中...)

前往app查看评论内容

#OTR#

SCI REP：尿液Endotrophin预测慢性肾脏疾病患者疾病进展！

2017-12-14

jichang (审核中...)

前往app查看评论内容

#OTR#

CFDA批准上市Votrient®（培唑帕尼），用于晚期肾细胞癌患者治疗

2017-12-02

jichang (审核中...)

前往app查看评论内容

#OTR#

CFDA批准上市Giotrif®（阿法替尼），单药治疗EGFR敏感突变的晚期非小细胞肺癌

2017-12-02

jichang (审核中...)

前往app查看评论内容

#OTR#

ASCO 2017：热点聚焦——新药Larotrectinib（LOXO-101）治疗各种成人及儿童癌症效果卓越

2017-06-07

jichang (审核中...)

前往app查看评论内容

#OTR#

疗效不佳，勃林格殷格翰终止两项Gilotrif 头颈癌临床试验

2016-08-10

jichang (审核中...)

前往app查看评论内容

#OTR#

J NEUROTRAUM：脑震荡后女孩酗酒风险增加，改变环境可降低风险

2015-10-17

jichang (审核中...)

前往app查看评论内容

#OTR#

The Lancet Oncology：勃林格靶向药物Giotrif治疗肺部鳞状细胞癌疗效优于Tarceva

2015-07-10

jichang (审核中...)

前往app查看评论内容

#OTR#

PLoS One：Tiotropium治疗慢性阻塞性肺病效果略优于Indacaterol

2015-04-01

jichang (审核中...)

前往app查看评论内容

#OTR#

Spine J：Cotrel-Dubousset 装置的棒大小不影响 AIS 患者的手术结果

2014-08-16

jichang (审核中...)

前往app查看评论内容

#OTR#

勃林格殷格翰向欧盟提交tiotropium Respimat®扩大适应症申请

2013-11-16

jichang (审核中...)

前往app查看评论内容

#OTR#

勃林格殷格翰抗癌药Giotrif（afatinib）获欧盟批准

2013-10-10

jichang (审核中...)

前往app查看评论内容

#OTR#

FDA：葛兰素史克向欧盟提交Votrient新适应症申请

2013-08-10

jichang (审核中...)

前往app查看评论内容

#OTR#

FDA批准Gilotrif用于肺癌患者

2013-08-02

科室
- - 订阅+
  - 更多科室
工具
服务